[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (1,853)

Search Parameters:
Keywords = virtual screening

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
21 pages, 4921 KiB  
Article
In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach
by Gabriele La Monica, Federica Alamia, Alessia Bono, Francesco Mingoia, Annamaria Martorana and Antonino Lauria
Molecules 2024, 29(24), 6040; https://doi.org/10.3390/molecules29246040 (registering DOI) - 21 Dec 2024
Viewed by 295
Abstract
Breast cancer remains one of the most prevalent and lethal malignancies in women, particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately 70% of cases. Traditional endocrine therapies, including aromatase inhibitors, selective estrogen receptor degraders/antagonists (SERDs), and selective estrogen receptor modulators (SERMs), [...] Read more.
Breast cancer remains one of the most prevalent and lethal malignancies in women, particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately 70% of cases. Traditional endocrine therapies, including aromatase inhibitors, selective estrogen receptor degraders/antagonists (SERDs), and selective estrogen receptor modulators (SERMs), have improved outcomes for metastatic ER+ breast cancer. However, resistance to these agents presents a significant challenge. This study explores a novel therapeutic strategy involving the simultaneous inhibition of the estrogen receptor (ER) and the chaperone protein Hsp90, which is crucial for the stabilization of various oncoproteins, including ER itself. We employed a hybrid, hierarchical in silico virtual screening approach to identify new dual ER/Hsp90 inhibitors, utilizing the Biotarget Predictor Tool (BPT) for efficient multitarget screening of a large compound library. Subsequent structure-based studies, including molecular docking analyses, were conducted to further evaluate the interaction of the top candidates with both ER and Hsp90. Supporting this, molecular dynamics simulations demonstrate the high stability of the multitarget inhibitor 755435 in complex with ER and Hsp90. Our findings suggest that several small molecules, particularly compound 755435, exhibit promising potential as dual inhibitors, representing a new avenue to overcome resistance in ER+ breast cancer. Full article
Show Figures

Figure 1

Figure 1
<p>X-ray structure of the ER ligand binding pocket (PDB code 7KBS [<a href="#B40-molecules-29-06040" class="html-bibr">40</a>]).</p>
Full article ">Figure 2
<p>X-ray structure of the Hsp90 ligand binding pocket (PDB code 2FWY [<a href="#B42-molecules-29-06040" class="html-bibr">42</a>]).</p>
Full article ">Figure 3
<p>(<b>a</b>) Calculated RMSD during 100 ns of the simulation trajectory for the <b>743414</b>/ER complex; (<b>b</b>) calculated RMSD during 100 ns of the simulation trajectory for the <b>676315</b>/ER complex; (<b>c</b>) calculated RMSD during 100 ns of the simulation trajectory for the <b>755435</b>/ER complex; (<b>d</b>) calculated RMSD during 100 ns of the simulation trajectory for the <span class="html-italic">raloxifene</span>/ER complex.</p>
Full article ">Figure 4
<p>(<b>a</b>) Calculated RMSD during 100 ns of the simulation trajectory for the <b>743414</b>/Hsp90 complex; (<b>b</b>) calculated RMSD during 100 ns of the simulation trajectory for the <b>676315</b>/Hsp90 complex; (<b>c</b>) calculated RMSD during 100 ns of the simulation trajectory for the <b>755435</b>/Hsp90 complex; (<b>d</b>) calculated RMSD during 100 ns of the simulation trajectory for the <span class="html-italic">PF-04929113</span>/Hsp90 complex; (<b>e</b>) calculated RMSD during 100 ns of the simulation trajectory for the <span class="html-italic">UP-H64</span>/Hsp90 complex.</p>
Full article ">Figure 5
<p>(<b>a</b>) Calculated P-RMSF during the simulation for Hsp90 in complex with <b>755435</b>; (<b>b</b>) calculated P-RMSF during the simulation for ER in complex with <b>755435</b>.</p>
Full article ">Figure 6
<p>(<b>a</b>) Two-dimensional structure of compound <b>755435</b>; (<b>b</b>) calculated L-RMSF during the simulation for <b>755435</b> in complex with ER; (<b>c</b>) calculated L-RMSF during the simulation for <b>755435</b> in complex with Hsp90.</p>
Full article ">Figure 7
<p>(<b>a</b>) Three-dimensional binding site of ER in complex with <span class="html-italic">raloxifene</span> (PDB code 7KBS); (<b>b</b>) Hsp90 in complex with <span class="html-italic">UP-H64</span> (PDB code 2FWY); (<b>c</b>) Hsp90 in complex with <span class="html-italic">PF-04929113</span> (PDB code 2FWY). Interaction color legend: yellow—hydrogen bonds; pink—salt bridge; green—Pi–cation interaction; blue—Pi-Pi stacking interaction.</p>
Full article ">Figure 8
<p>(<b>a</b>) Two-dimensional structure of the detailed interactions between the atoms of ligand <b>755435</b> and the protein residues of ER; (<b>b</b>) three-dimensional binding site of <b>755435</b> in complex with ER (PDB code 7KBS).</p>
Full article ">Figure 9
<p>(<b>a</b>) Two-dimensional structure of the detailed interactions between the atoms of ligand <b>755435</b> and the protein residues of Hsp90; (<b>b</b>) three-dimensional binding site of <b>755435</b> in complex with Hsp90 (PDB code 2FWY).</p>
Full article ">Figure 10
<p>(<b>a</b>) Protein–ligand interactions examination across the simulation time for <b>755435</b>/ER complex; (<b>b</b>) protein–ligand interactions examination across the simulation time for <b>755435</b>/Hsp90 complex.</p>
Full article ">
7 pages, 2081 KiB  
Proceeding Paper
Prototype of a Public Computer System with Fast Automatic Touchscreen Disinfection by Integrated UVC LEDs and Total Reflection
by Sebastian Deuschl, Ben Sicks, Helge Moritz and Martin Hessling
Phys. Sci. Forum 2024, 10(1), 3; https://doi.org/10.3390/psf10010000 - 17 Dec 2024
Viewed by 59
Abstract
Public touchscreens, such as those used in automated teller machines or ticket payment systems, which are accessed by different people in a short period of time, could transmit pathogens and thus spread infections. Therefore, the aim of this study was to develop and [...] Read more.
Public touchscreens, such as those used in automated teller machines or ticket payment systems, which are accessed by different people in a short period of time, could transmit pathogens and thus spread infections. Therefore, the aim of this study was to develop and test a prototype of a touchscreen system for the public sector that disinfects itself quickly and automatically between two users without harming any humans. A quartz pane was installed in front of a commercial 19” monitor, into which 120 UVC LEDs emitted laterally. The quartz plate acted as a light guide and irradiated microorganisms on its surface, but—due to total reflection—not the user in front of the screen. A near-infrared commercial touch frame was installed to recognize touch. The antibacterial effect was tested through intentional staphylococcus contamination. The prototype, composed of a Raspberry Pi microcomputer with a display, a touchscreen, and a touch frame, was developed, and a simple game was programmed that briefly switched on the UVC LEDs between two users. The antimicrobial effect was so strong that 1% of the maximum UVC LED current was sufficient for a 99.9% staphylococcus reduction within 25 s. At 17.5% of the maximum current, no bacteria were observed after 5 s. The residual UVC irradiance at a distance of 100 mm in front of the screen was only 0.18 and 2.8 µW/cm2 for the two currents, respectively. This would allow users to stay in front of the system for 287 or 18 min, even if the LEDs were to emit UVC continuously and not be turned off after a few seconds as in the presented device. Therefore, fast, automatic touchscreen disinfection with UVC LEDs is already possible today, and with higher currents, disinfection durations below 1 s seems to be feasible, while the light guide approach virtually prevents the direct irradiation of the human user. Full article
(This article belongs to the Proceedings of The 1st International Online Conference on Photonics)
Show Figures

Figure 1

Figure 1
<p>Schematic top view of the setup with quartz plate, touch frame, and UVC LEDs.</p>
Full article ">Figure 2
<p>Schematic cross section of the setup with commercial monitor, bacterial contaminated quartz plate, touch frame, and UVC LEDs. The LEDs were switched off when a touch was recognized.</p>
Full article ">Figure 3
<p>Example screen shots from the game and the subsequent disinfection.</p>
Full article ">Figure 4
<p>Average staphylococcus reduction with 20 mA LED current in half-logarithmic representation. The error bars give the standard deviation of the single runs, while the linear trend line illustrates the exponential character of the bacterial decrease.</p>
Full article ">
32 pages, 9784 KiB  
Article
Discovery of Non-Peptide GLP-1 Positive Allosteric Modulators from Natural Products: Virtual Screening, Molecular Dynamics, ADMET Profiling, Repurposing, and Chemical Scaffolds Identification
by Mohamed S. Gomaa, Mansour S. Alturki, Nada Tawfeeq, Dania A. Hussein, Faheem H. Pottoo, Abdulaziz H. Al Khzem, Mohammad Sarafroz and Samar Abubshait
Pharmaceutics 2024, 16(12), 1607; https://doi.org/10.3390/pharmaceutics16121607 - 17 Dec 2024
Viewed by 330
Abstract
Background/Objectives: Glucagon-like peptide-1 (GLP-1) receptor is currently one of the most explored targets exploited for the management of diabetes and obesity, with many aspects of its mechanisms behind cardiovascular protection yet to be fully elucidated. Research dedicated towards the development of oral GLP-1 [...] Read more.
Background/Objectives: Glucagon-like peptide-1 (GLP-1) receptor is currently one of the most explored targets exploited for the management of diabetes and obesity, with many aspects of its mechanisms behind cardiovascular protection yet to be fully elucidated. Research dedicated towards the development of oral GLP-1 therapy and non-peptide ligands with broader clinical applications is crucial towards unveiling the full therapeutic capacity of this potent class of medicines. Methods: This study describes the virtual screening of a natural product database consisting of 695,133 compounds for positive GLP-1 allosteric modulation. The database, obtained from the Coconut website, was filtered according to a set of physicochemical descriptors, then was shape screened against the crystal ligand conformation. This filtered database consisting of 26,325 compounds was used for virtual screening against the GLP-1 allosteric site. Results: The results identified ten best hits with the XP score ranging from −9.6 to −7.6 and MM-GBSA scores ranging from −50.8 to −32.4 and another 58 hits from docked pose filter and a second round of XP docking and MM-GBSA calculation followed by molecular dynamics. The analysis of results identified hits from various natural products (NPs) classes, to whom attributed antidiabetic and anti-obesity effects have been previously reported. The results also pointed to β-lactam antibiotics that may be evaluated in drug repurposing studies for off-target effects. The calculated ADMET properties for those hits revealed suitable profiles for further development in terms of bioavailability and toxicity. Conclusions: The current study identified several NPs as potential GLP-1 positive allosteric modulators and revealed common structural scaffolds including peptidomimetics, lactams, coumarins, and sulfonamides with peptidomimetics being the most prominent especially in indole and coumarin cores. Full article
(This article belongs to the Special Issue Computer-Aided Development: Recent Advances and Expectations)
Show Figures

Figure 1

Figure 1
<p>Filtration protocol for the Coconut natural products database.</p>
Full article ">Figure 2
<p>Chemical structure of GLP-1 co-crystallized ligands positive allosteric modulator used in the shape screening.</p>
Full article ">Figure 3
<p>Hit identification protocol.</p>
Full article ">Figure 4
<p>Surface representation of the overlay of the top 10 hits (magenta sticks) and the crystal ligand (red stick) in GLP-1 allosteric site (PDB ID: 6VCB). GLP-1 receptor is represented in gray surface and GLP-1 peptide in green surface.</p>
Full article ">Figure 5
<p>(<b>a</b>) Three-dimensional representation of the binding interactions between hit <b>1</b> and GLP-1 receptor allosteric site and GLP-1 peptide (PDB ID: 6VCB). Ligand atoms are shown as sticks (carbon atoms colored in magenta) and the key residues are shown as sticks (carbon atoms colored in green). Potential electrostatic interactions are represented as yellow dotted lines and are measured in Angstrom. (<b>b</b>) Two-dimensional ligand–protein binding interactions between hit <b>1</b> and GLP-1 receptor allosteric site and GLP-1 peptide (PDB ID: 6VCB). H bond is represented as a purple arrow and salt bridge as a blue line.</p>
Full article ">Figure 6
<p>(<b>a</b>) Three-dimensional representation of the binding interactions between hit <b>12</b> and GLP-1 receptor allosteric site and GLP-1 peptide (PDB ID: 6VCB). Ligand atoms are shown as sticks (carbon atoms colored in magenta) and the key residues are shown as sticks (carbon atoms colored in green). Potential electrostatic interactions are represented as yellow dotted lines and are measured in Angstrom. (<b>b</b>) Two-dimensional ligand–protein binding interactions between hit <b>12</b> and GLP-1 receptor allosteric site and GLP-1 peptide (PDB ID: 6VCB). H bond is represented as a purple arrow, salt bridge as a blue line, and π-π stacking as a green line.</p>
Full article ">Figure 7
<p>(<b>a</b>) Three-dimensional representation of the binding interactions between hit <b>44</b> (Ampicillin) and GLP-1 receptor allosteric site and GLP-1 peptide (PDB ID: 6VCB). Ligand atoms are shown as sticks (carbon atoms colored in magenta) and the key residues are shown as sticks (carbon atoms colored in green). Potential electrostatic interactions are represented as yellow dotted lines and are measured in Angstrom. (<b>b</b>) Two-dimensional ligand–protein binding interactions between hit <b>44</b> (Ampicillin) and GLP-1 receptor allosteric site and GLP-1 peptide (PDB ID: 6VCB). H bond is represented as a purple arrow, and salt bridge as a blue line.</p>
Full article ">Figure 8
<p>Root mean square deviation (RMSD) graphs for the hit compounds (<b>A</b>): compound <b>3</b> (CNP0086660.2), (<b>B</b>): compound <b>5</b> (CNP0039190.2), (<b>C</b>): compound <b>2</b> (CNP0549010.1). The green graph shows fluctuations in the protein backbone from the initial reference point while the red shows the ligand fluctuations. The RMSD profile of the ligand with respect to its initial fit to the protein binding pocket indicates that all ligands did not fluctuate beyond a 2–7 Å range.</p>
Full article ">Figure 9
<p>Interaction diagram of hit compound <b>3</b> (CNP0086660.2) with the GLP-1 allosteric binding pocket. (<b>A</b>) Interaction of compound <b>3</b> with residues in each trajectory frame. The depth of color indicating the higher the interaction with contact residues; (<b>B</b>) the protein–ligand contacts showing the bonding interactions fraction and the nature of the interactions; (<b>C</b>) graphical 2D illustration of compound <b>3</b> interacting with the protein residues during MD simulation.</p>
Full article ">Figure 10
<p>Interaction diagram of hit compound <b>5</b> (CNP0039190.2) with the GLP-1 allosteric binding pocket. (<b>A</b>) Interaction of compound <b>5</b> with residues in each trajectory frame. The depth of color indicating the higher the interaction with contact residues; (<b>B</b>) the protein–ligand contacts showing the bonding interactions fraction and the nature of the interactions; (<b>C</b>) graphical 2D illustration of compound <b>5</b> interacting with the protein residues during MD simulation.</p>
Full article ">Figure 11
<p>Interaction diagram of hit compound <b>2</b> (CNP0549010.1) with the GLP-1 allosteric binding pocket. (<b>A</b>) Interaction of compound <b>2</b> with residues in each trajectory frame. The depth of color indicating the higher the interaction with contact residues; (<b>B</b>) the protein–ligand contacts showing the bonding interactions fraction and the nature of the interactions; (<b>C</b>) graphical 2D illustration of compound <b>2</b> interacting with the protein residues during MD simulation.</p>
Full article ">Figure 12
<p>Chemical structures of identified novel scaffolds for GLP-1 positive allosteric modulation with their hit no (hits are arranged according to their XP/Docking score), Coconut ID, and XP/Docking score.</p>
Full article ">Figure 12 Cont.
<p>Chemical structures of identified novel scaffolds for GLP-1 positive allosteric modulation with their hit no (hits are arranged according to their XP/Docking score), Coconut ID, and XP/Docking score.</p>
Full article ">Figure 12 Cont.
<p>Chemical structures of identified novel scaffolds for GLP-1 positive allosteric modulation with their hit no (hits are arranged according to their XP/Docking score), Coconut ID, and XP/Docking score.</p>
Full article ">Figure 12 Cont.
<p>Chemical structures of identified novel scaffolds for GLP-1 positive allosteric modulation with their hit no (hits are arranged according to their XP/Docking score), Coconut ID, and XP/Docking score.</p>
Full article ">Figure 12 Cont.
<p>Chemical structures of identified novel scaffolds for GLP-1 positive allosteric modulation with their hit no (hits are arranged according to their XP/Docking score), Coconut ID, and XP/Docking score.</p>
Full article ">
25 pages, 35789 KiB  
Review
Three-Dimensional Ultrasound for Physical and Virtual Fetal Heart Models: Current Status and Future Perspectives
by Nathalie Jeanne Bravo-Valenzuela, Marcela Castro Giffoni, Caroline de Oliveira Nieblas, Heron Werner, Gabriele Tonni, Roberta Granese, Luis Flávio Gonçalves and Edward Araujo Júnior
J. Clin. Med. 2024, 13(24), 7605; https://doi.org/10.3390/jcm13247605 - 13 Dec 2024
Viewed by 448
Abstract
Congenital heart defects (CHDs) are the most common congenital defect, occurring in approximately 1 in 100 live births and being a leading cause of perinatal morbidity and mortality. Of note, approximately 25% of these defects are classified as critical, requiring immediate postnatal care [...] Read more.
Congenital heart defects (CHDs) are the most common congenital defect, occurring in approximately 1 in 100 live births and being a leading cause of perinatal morbidity and mortality. Of note, approximately 25% of these defects are classified as critical, requiring immediate postnatal care by pediatric cardiology and neonatal cardiac surgery teams. Consequently, early and accurate diagnosis of CHD is key to proper prenatal and postnatal monitoring in a tertiary care setting. In this scenario, fetal echocardiography is considered the gold standard imaging ultrasound method for the diagnosis of CHD. However, the availability of this examination in clinical practice remains limited due to the need for a qualified specialist in pediatric cardiology. Moreover, in light of the relatively low prevalence of CHD among at-risk populations (approximately 10%), ultrasound cardiac screening for potential cardiac anomalies during routine second-trimester obstetric ultrasound scans represents a pivotal aspect of diagnosing CHD. In order to maximize the accuracy of CHD diagnoses, the views of the ventricular outflow tract and the superior mediastinum were added to the four-chamber view of the fetal heart for routine ultrasound screening according to international guidelines. In this context, four-dimensional spatio-temporal image correlation software (STIC) was developed in the early 2000s. Some of the advantages of STIC in fetal cardiac evaluation include the enrichment of anatomical details of fetal cardiac images in the absence of the pregnant woman and the ability to send volumes for analysis by an expert in fetal cardiology by an internet link. Sequentially, new technologies have been developed, such as fetal intelligent navigation echocardiography (FINE), also known as “5D heart”, in which the nine fetal cardiac views recommended during a fetal echocardiogram are automatically generated from the acquisition of a cardiac volume. Furthermore, artificial intelligence (AI) has recently emerged as a promising technological innovation, offering the potential to warn of possible cardiac anomalies and thus increase the ability of non-cardiology specialists to diagnose CHD. In the early 2010s, the advent of 3D reconstruction software combined with high-definition printers enabled the virtual and 3D physical reconstruction of the fetal heart. The 3D physical models may improve parental counseling of fetal CHD, maternal–fetal interaction in cases of blind pregnant women, and interactive discussions among multidisciplinary health teams. In addition, the 3D physical and virtual models can be an useful tool for teaching cardiovascular anatomy and to optimize surgical planning, enabling simulation rooms for surgical procedures. Therefore, in this review, the authors discuss advanced image technologies that may optimize prenatal diagnoses of CHDs. Full article
(This article belongs to the Section Obstetrics & Gynecology)
Show Figures

Figure 1

Figure 1
<p>Measurements of interventricular septum volume (IVS) using 3D ultrasound with STIC and virtual organ computer-aided analysis (VOCAL) in a fetus from a diabetic mother at 25 weeks of gestation. IVS volume = 0.144 cm<sup>3</sup>.</p>
Full article ">Figure 2
<p>Left ventricle diastolic volume using STIC with virtual organ computer-aided analysis (VOCAL) in a fetus at 30 weeks of gestation. LV volume = 1.3 cm<sup>3</sup>.</p>
Full article ">Figure 3
<p>Evaluation of the tricuspid annular movement using fetal STIC-M (5.4 mm). TAPSE: tricuspid annular plane systolic excursion; RV: right ventricle.</p>
Full article ">Figure 4
<p>Three-dimensional ultrasound with STIC: (<b>A</b>) HDlive mode, providing a reconstruction of the left ventricular outflow tract in a case of transposition of the great arteries and (<b>B</b>) with color Doppler in a first-trimester fetus with tetralogy of Fallot. Observe the pulmonary artery (P) arising from the left ventricle (LV) in image (<b>A</b>) and the overriding of the aorta (<b>A</b>) in image (<b>B</b>). RV: right ventricle; LV: left ventricle; VSD: ventricular septal defect; IVS: ventricular septum.</p>
Full article ">Figure 5
<p>Tomographic ultrasound imaging (TUI) in the rendering mode enables the visualization of sequential axial planes in the case of inlet ventricular septal defect (VSD) (yellow arrows).</p>
Full article ">Figure 6
<p>STIC with HDlive Silhouette mode in a case of coarctation of aorta. Note the discrepancy of the great arteries due to the small aorta. AO: aorta; PA: pulmonary artery; VC: superior vena cava.</p>
Full article ">Figure 7
<p>(<b>A</b>) Three-dimensional ultrasound with Surface Realistic Vue (SRV) imaging in a case of partial anomalous pulmonary vein return with a ventricular septal defect (VSD). Note that 2 of the pulmonary veins return to the right atrium (red arrows). Virtual light source position, 10 o’clock. (<b>B</b>) STIC with color Doppler of a case of total anomalous pulmonary vein return (infradiaphragmatic type). The right (RPV) and left pulmonary veins (LPVs) drain (white arrows) into a collecting vein (COL) and subsequently into a vertical vein (VV), which achieves the right atrium (RA) via the inferior vena cava (IVC). LV: left ventricle; LA: left atrium; RA: right atrium; RV: right ventricle; ** VSD: ventricular septal defect; PV: pulmonary vein; T: tricuspid valve; M: mitral valve.</p>
Full article ">Figure 8
<p>Three-dimensional ultrasound with STIC and HDlive mode in a case of left heterotaxy. Observe that the venous vessel (hemiazygos) is located posteriorly (near to the fetal spine) to the arterial vessel (aorta) at the upper abdomen view. Ao; aorta; Hz: hemiazygos vein; L: fetal left side; R: fetal right side.</p>
Full article ">Figure 9
<p>Extra-hepatic form of agenesis of ductus venosus using three-dimensional ultrasound with STIC. Note the high-resolution color Doppler showing the absence of flow through the DV (red arrow). In this case, the umbilical vein drains into the RA via the inferior vena cava. IVC: inferior vena cava; RA: right atrium.</p>
Full article ">Figure 10
<p>Three-dimensional ultrasound with STIC enabling the reconstruction of the ventricular outflow tracts in a case of double-outlet right vetricle (“Taussig-Bing” anomaly). Note the great arteries arising from the right ventricle (RV) in a parallel relationship. Ao: aorta; PA: pulmonary artery.</p>
Full article ">Figure 11
<p>Tomographic ultrasound imaging (TUI) in the rendering mode in a case of tetralogy of Fallot and in (<b>B</b>) double outflow of the right ventricle (DORV). The right ventricle hypertrophy (yellow arrows) could be observed using this technology (<b>A</b>). Note the great arteries in a parallel relationship (red arrows) in a fetus with Taussig–Bing DORV using color Doppler (<b>B</b>). DORV: double outflow of right ventricle; Ao; aorta; P: pulmonary artery.</p>
Full article ">Figure 12
<p>The reconstruction of the ventricular outflow tracts in a case of transposition of the great arteries (TGA) using STIC with color Doppler (<b>A</b>) and HDlive Silhouette. In image (<b>A</b>), it is evident that the aorta (Ao) arises from the right ventricle (RV). In image (<b>B</b>), the pulmonary artery (PA) is unequivocally identified as originating from the left ventricle (LV). The two arteries are observed to be in a parallel relationship (red arrows), with the aorta located anteriorly to the PA.</p>
Full article ">Figure 13
<p>Three-dimensional ultrasound with STIC in the rendering mode: the measurement of the area of the foramen ovale (FO) was obtained from the four-chamber view of the fetal heart in which the ROI (green line) is the flap of the FO. ROI: region of interest.</p>
Full article ">Figure 14
<p>Three-dimensional with STIC in the rendering mode (<b>A</b>) and HDlive mode (<b>B</b>) of a fetus with Ebstein’s anomaly at 30 weeks of gestation. RA: right atrium; T: tricuspid valve; RV: right ventricle; LA: left atrium; M: mitral valve LV: left ventricle.</p>
Full article ">Figure 15
<p>(<b>A</b>) Reconstruction of the aortic arch using STIC with the inversion mode in a case of coarctation of the aorta. Observe the narrowing of the aortic isthmus (yellow arrow). (<b>B</b>) Aortic and duct arch imaging in a fetus with a normal heart. (<b>B</b>) Sagittal view of a fetus with a normal heart showing the aortic and ductal arches using LumiFlow. (<b>C</b>) First-trimester imaging using HDFlow in a fetus with a right aortic arch (red arrow) and vascular ring (observe the vessels around the trachea). Ao: aorta; BCT: brachiocephalic trunk; LCC: left common carotid; LSCA: left subclavian artery; P: pulmonary artery; DA: ductus arteriosus; Tr: trachea; R: right side; L: left side.</p>
Full article ">Figure 16
<p>Large mass (**) in the ventricular septum and both ventricles, mainly in the left ventricle, in a case of rhabdomyomas with a reduction in the size of the masses after prenatal therapy with sirolimus. LV: left ventricle; LA: left atrium; RA: right atrium; RV: right ventricle; T: tricuspid valve.</p>
Full article ">Figure 17
<p>STIC-M enabling the measurement of mitral annular plane systolic excursion (MAPSE) (5.4 mm). LV: left ventricle.</p>
Full article ">Figure 18
<p>Three-dimensional reconstruction of the left ventricle (LV) using STIC with virtual organ computer-aided analysis (VOCAL) in a fetus at 22 weeks of gestation.</p>
Full article ">Figure 19
<p>FINE navigation (known as “5D heart”) in (<b>A</b>) a case of a malalignment type of ventricular septal defect (***, yellow arrows) and in (<b>B</b>) a case of complete atrioventricular septal defect (AVSD). In case (<b>A</b>), observe the overriding of the aorta (Ao). In case (<b>B</b>), observe that the four-chamber, the five-chamber, and LV outflow tract (LVOT) views (yellow arrows) draw attention to this diagnosis. *** Common AV valve; VSD: ventricular septal defect; ASD: primum atrial septal defect; GN: LVOT with a “goose neck” shape.</p>
Full article ">Figure 20
<p>Automatic measurement of the fetal the cardiac axis (40.3º) using artificial intelligence (“Learning Machine”) in a normal heart using fetal intelligent navigation echocardiography (FINE), also known as “5D Heart”. LV: left ventricle; LA: left atrium; RA: right atrium; RV: right ventricle; A or Ao: aorta; P or PA: pulmonary artery; S: superior vena cava; IVC: inferior vena cava; Desc: descending; Trans: transverse.</p>
Full article ">Figure 21
<p>First-trimester measurement of the cardiac axis (45°) of a normal fetus (yellow arrow). L: left side; R:right side: Ao: aorta; S: spine.</p>
Full article ">Figure 22
<p>Three-dimensional physical model of a fetus with transposition of the great arteries (TGA). RV: right ventricle; Ao: aorta; LV: left ventricle; P: pulmonary artery.</p>
Full article ">Figure 23
<p>Three-dimensional virtual model of fetal heart in a fetus with transposition of the great arteries (TGA) (<b>A</b>) and in a fetus with Ebstein’s anomaly (<b>B</b>). RA: right atrium; RV: right ventricle; LA: left atrium; T: tricuspid valve; M: mitral valve; LV: left ventricle; Ao: aorta; P: pulmonary artery.</p>
Full article ">Figure 24
<p>Following the acquisition of images of the fetal heart with tetralogy of Fallot from 3D ultrasound (heart volumes) using tools from Slicer 3D software (Birmingham, UK), the cardiac structures were segmented, with each cavity identified by a different color (right and left atrium, right and left ventricles, aorta, pulmonary artery, vena cava and pulmonary veins). Thereafter, a raw file format was generated. Based on the 3D data, physical 3D models of the fetal heart were printed using a 3D printer. Ao: aorta; LA: left atrium; P: pulmonary artery; RA: right atrium; LV: left ventricle; RV: right ventricle; VSD: ventricular septal defect.</p>
Full article ">Figure 25
<p>(<b>A</b>) Fetal cardiac MRI (fCMR) performed at 32 weeks and 5 days. Images were obtained at 1.5 T using a balanced turbo field echo (BTFE) sequence, gated with an MRI-compatible Doppler ultrasound (DUS) device (North Medical, Hamburg, Germany). Four-chamber view in systole (<b>A</b>) and diastole (<b>B</b>). LA: left atrium; LV: left ventricle; RA: right atrium; LA: left atrium.</p>
Full article ">Figure 26
<p>Multiplanar display images of a case of hypoplastic left heart syndrome examined at 32 weeks and 3 days. The images were acquired using a balanced turbo field echo (BTFE) sequence at 1.5 T. kt-sense acceleration was used during acquisition. The images were postprocessed using a super-resolution pipeline, resulting in an isovoxel 3D volume dataset. (<b>A</b>) Sagittal two-chamber view. (<b>B</b>) Four-chamber view. (<b>C</b>) Coronal short-axis view through the ventricles. LA: left atrium; LV: left ventricle; RA: right atrium; RV: right ventricle.</p>
Full article ">
22 pages, 4886 KiB  
Article
A Fuzzy-Control Anti-Cybersickness Intelligent System (FCACIS) Designed for Multiple Inducing Factors in a 3D Virtual Store
by Cheng-Li Liu and Shiaw-Tsyr Uang
Appl. Sci. 2024, 14(24), 11609; https://doi.org/10.3390/app142411609 - 12 Dec 2024
Viewed by 352
Abstract
As online shopping has increased, the business models of online stores have diversified. When consumers cannot experience an actual product, merchants will promote products through a display to attract customers. Virtual reality (VR) provides an immersive platform for consumers to interact with virtual [...] Read more.
As online shopping has increased, the business models of online stores have diversified. When consumers cannot experience an actual product, merchants will promote products through a display to attract customers. Virtual reality (VR) provides an immersive platform for consumers to interact with virtual scenarios. Unfortunately, cybersickness remains a problem in VR. The uncomfortable effects of VR hinder its commercial expansion and the broader adoption of 3D virtual stores. Cybersickness has many causes, including personal characteristics, hardware interfaces, and operation behavior. This study develops a fuzzy-control anti-cybersickness intelligent system (FCACIS) with these factors dynamically and actively. The system retrieves the operation value and inferences the cybersickness symptom value (CSSV). When the CSSV exceeds the alarm value, a dialog mode is introduced to remind users to be aware of possible cybersickness. If the CSSV continues to increase, a cybersickness defense mechanism is activated, such as decreasing the field of view and freezing the screen. The experimental results revealed a significant difference in SSQ scores between subjects who navigated a 3D virtual store with and without the FCACIS. The SSQ scores of subjects with the FCACIS (SSQ = 20.570) were significantly lower than those of subjects without the FCACIS (SSQ = 32.880). The FCACIS effectively alleviated cybersickness for subjects over 40 years old. Additionally, the FCACIS effectively slowed the onset of cybersickness in men and women. The anti-cybersickness effect of the FCACIS on flat-panel displays was greater than that on HMDs. The symptoms of cybersickness for a 3DOF controller were also reduced. Full article
(This article belongs to the Special Issue Human–Computer Interaction and Virtual Environments)
Show Figures

Figure 1

Figure 1
<p>Architecture of the virtual store’s intelligent anti-cybersickness design.</p>
Full article ">Figure 2
<p>Emotion assessment system: (<b>a</b>) happy mood: the user checks the optimal state corresponding to the current happiness level; (<b>b</b>) excited mood: the user evaluates the excitement level before entering the 3D virtual store; (<b>c</b>) control desire: the user indicates the extent to which he or she wants to control store navigation after entering the 3D virtual store.</p>
Full article ">Figure 3
<p>Depth perception ability assessment: The user judges the distance between the two pillars that appear in the window and uses the control keys “↑” and “↓” to adjust their front and rear positions for confirmation. When the positions of the two pillars appear equidistant, the confirm button is pressed. (<b>a</b>) shows that the left pillar is closer to the subject; (<b>b</b>) shows that the right pillar is closer to the subject. The top image is the image shown to the subject, and the bottom image shows the actual locations.</p>
Full article ">Figure 4
<p>The fuzzy membership functions No, Slight, Mild, Moderate, and Serious for the output fuzzy set <span class="html-italic">μR<sub>k</sub></span> (<span class="html-italic">r</span>).</p>
Full article ">Figure 5
<p>Scene of the 3D virtual store: (<b>a</b>) layout of the 3D virtual store; (<b>b</b>) part of the scene.</p>
Full article ">Figure 6
<p>An alarm signal appears in the 3D virtual store for approximately 10 s to warn the user when the CSSV exceeds 7.5.</p>
Full article ">Figure 7
<p>When the CSSV reaches 15, a blur filter appears on the 3D virtual store display to narrow the field of view. (<b>a</b>) When the CSSV is 15, a filter with 50% transparency appears; (<b>b</b>) when the CSSV reaches 18, the filter transparency decreases to 25%; (<b>c</b>) when the CSSV reaches 21, the filter transparency decreases to 10%.</p>
Full article ">Figure 8
<p>(<b>a</b>) Proportions of SSQ scores obtained by subjects in the three major categories with and without the FCACIS. (<b>b</b>) The average SSQ scores in the three major categories obtained by the subjects with and without the FCACIS.</p>
Full article ">Figure 9
<p>The average SSQ scores in the three major categories obtained for different sexes with and without the FCACIS.</p>
Full article ">Figure 10
<p>Average SSQ scores in three major categories obtained by subjects of different age groups with and without the FCACIS.</p>
Full article ">Figure 11
<p>The average SSQ scores in the three major categories obtained by subjects of different ages with and without the FCACIS.</p>
Full article ">Figure 12
<p>The average SSQ scores in the three major categories obtained by different displays with and without the FCACIS.</p>
Full article ">
27 pages, 3670 KiB  
Article
Helichrysum populifolium Compounds Inhibit MtrCDE Efflux Pump Transport Protein for the Potential Management of Gonorrhoea Infection
by Vhangani E. Mulaudzi, Idowu J. Adeosun, Adeniyi T. Adewumi, Mahmoud E. S. Soliman and Sekelwa Cosa
Int. J. Mol. Sci. 2024, 25(24), 13310; https://doi.org/10.3390/ijms252413310 - 11 Dec 2024
Viewed by 518
Abstract
The progressive development of resistance in Neisseria gonorrhoeae to almost all available antibiotics has made it crucial to develop novel approaches to tackling multi-drug resistance (MDR). One of the primary causes of antibiotic resistance is the over-expression of the MtrCDE efflux pump protein, [...] Read more.
The progressive development of resistance in Neisseria gonorrhoeae to almost all available antibiotics has made it crucial to develop novel approaches to tackling multi-drug resistance (MDR). One of the primary causes of antibiotic resistance is the over-expression of the MtrCDE efflux pump protein, making this protein a vital target for fighting against antimicrobial resistance (AMR) in N. gonorrhoeae. This study was aimed at evaluating the potential MtrCDE efflux pump inhibitors (EPIs) and their stability in treating gonorrhoea infection. This is significant because finding novel EPIs would allow for the longer maintenance of antibiotics at therapeutic levels, thereby prolonging the susceptibility of currently available antibiotics. A virtual screening of the selected Helichrysum populifolium compounds (4,5-dicaffeoylquinic acid, apigeninin-7-glucoside, and carvacrol) was conducted to evaluate their potential EPI activity. An integrated computational framework consisting of molecular docking (MD), molecular mechanics generalized born, and surface area solvation (MMGBSA) analysis, molecular dynamics simulations (MDS), and absorption, distribution, metabolism, and excretion (ADME) properties calculations were conducted. Of the tested compounds, 4,5-dicaffeoylquinic acid revealed the highest molecular docking binding energies (−8.8 kcal/mol), equivalent MMGBSA binding free energy (−54.82 kcal/mol), indicative of consistent binding affinity with the MtrD protein, reduced deviations and flexibility (root mean square deviation (RMSD) of 5.65 Å) and, given by root mean square fluctuation (RMSF) of 1.877 Å. Carvacrol revealed a docking score of −6.0 kcal/mol and a MMGBSA computed BFE of −16.69 kcal/mol, demonstrating the lowest binding affinity to the MtrD efflux pump compared to the remaining test compounds. However, the average RMSD (4.45 Å) and RMSF (1.638 Å) of carvacrol-bound MtrD protein showed no significant difference from the unbound MtrD protein, except for the reference compounds, implying consistent MtrD conformation throughout simulations and indicates a desirable feature during drug design. Additionally, carvacrol obeyed the Lipinski rule of five which confirmed the compound’s drug-likeness properties making it the most promising EPI candidate based on its combined attributes of a reasonable binding affinity, sustained stability during MDS, its obedience to the Lipinski rule of five and compliance with drug-likeness criteria. An in vitro validation of the potential EPI activities of H. populifolium compounds confirmed that 4,5-dicaffeoylquinic acid reduced the expulsion of the bis-benzimide dye by MtrCDE pump, while carvacrol showed low accumulation compared to other compounds. While 4,5-dicaffeoylquinic acid demonstrated the highest binding affinity in computational analysis and an EPI activity in vitro, it showed lower stability compared to the other compounds, as indicated in MDS. This leaves carvacrol, as a better EPI candidate for the management of gonorrhoea infection. Full article
Show Figures

Figure 1

Figure 1
<p>(<b>A</b>) Crystal structure of MtrCDE efflux pump protein from <span class="html-italic">Neisseria gonorrhoea</span> with its distinguished chains. (<b>B</b>) The crystal structure of the MtrD chain of the MtrCDE efflux pump used in this study for molecular docking and molecular dynamic simulations assays, which consists of the proximal and distal multi-drug-binding sites.</p>
Full article ">Figure 2
<p>Two-dimensional and three-dimensional interaction network between the MtrD (PDB ID: 6VKS) EP protein in <span class="html-italic">N. gonorrhoeae</span> and test compounds from <span class="html-italic">H. populifolium</span> generated after molecular docking. As the binding of these compounds within the MtrD efflux pump multi-drug-binding site was within the −5 to −15 kcal/mol an indication that these compounds can fit perfectly within the binding pockets of the MtrD multi-drug-binding site. Hydrogen bonds are noted by the green lines, pi–alkyl interactions by light-pink color, pi–pi T-shaped interaction with the dark pink color, pi–sulfur interaction with the orange color, and unfavorable donor-to-donor interactions with the red color. (<b>A</b>) 4,5-dicaffeoylquinic acid. (<b>B</b>) Apigenin-7-glucoside. (<b>C</b>) Carvacrol. (<b>D</b>) Phenylalanine-arginine-β-naphylamide (PaβN). (<b>E</b>) Quercetin.</p>
Full article ">Figure 2 Cont.
<p>Two-dimensional and three-dimensional interaction network between the MtrD (PDB ID: 6VKS) EP protein in <span class="html-italic">N. gonorrhoeae</span> and test compounds from <span class="html-italic">H. populifolium</span> generated after molecular docking. As the binding of these compounds within the MtrD efflux pump multi-drug-binding site was within the −5 to −15 kcal/mol an indication that these compounds can fit perfectly within the binding pockets of the MtrD multi-drug-binding site. Hydrogen bonds are noted by the green lines, pi–alkyl interactions by light-pink color, pi–pi T-shaped interaction with the dark pink color, pi–sulfur interaction with the orange color, and unfavorable donor-to-donor interactions with the red color. (<b>A</b>) 4,5-dicaffeoylquinic acid. (<b>B</b>) Apigenin-7-glucoside. (<b>C</b>) Carvacrol. (<b>D</b>) Phenylalanine-arginine-β-naphylamide (PaβN). (<b>E</b>) Quercetin.</p>
Full article ">Figure 2 Cont.
<p>Two-dimensional and three-dimensional interaction network between the MtrD (PDB ID: 6VKS) EP protein in <span class="html-italic">N. gonorrhoeae</span> and test compounds from <span class="html-italic">H. populifolium</span> generated after molecular docking. As the binding of these compounds within the MtrD efflux pump multi-drug-binding site was within the −5 to −15 kcal/mol an indication that these compounds can fit perfectly within the binding pockets of the MtrD multi-drug-binding site. Hydrogen bonds are noted by the green lines, pi–alkyl interactions by light-pink color, pi–pi T-shaped interaction with the dark pink color, pi–sulfur interaction with the orange color, and unfavorable donor-to-donor interactions with the red color. (<b>A</b>) 4,5-dicaffeoylquinic acid. (<b>B</b>) Apigenin-7-glucoside. (<b>C</b>) Carvacrol. (<b>D</b>) Phenylalanine-arginine-β-naphylamide (PaβN). (<b>E</b>) Quercetin.</p>
Full article ">Figure 3
<p>Per-residue energy contributions of the interacting residues of the MtrD protein (PDB ID: 6VKS) with the <span class="html-italic">H. populifolium</span> test compounds and standards. (<b>A</b>) 4,5-dicaffeoylquinic acid. (<b>B</b>) Apigenin-7-glucoside. (<b>C</b>) Carvacrol. (<b>D</b>) Phenylalanine-arginine-β-naphylamide (PaβN). (<b>E</b>) Quercetin.</p>
Full article ">Figure 4
<p>(<b>A</b>) Protein–ligand complex of the MtrD efflux pump bound by 4,5-dicaffeoylquinic acid in magenta. The yellow color on the MtrCDE efflux pump protein structure represents the proximal and distal multi-drug efflux pump residues interacting with 4,5-dicaffeoylquinic acid. (<b>B</b>) Comparative C-α RMSD plots displaying the degree of stability and convergence of the studied compounds when bound to the MtrD protein for a period of 175 ns. (<b>C</b>) Comparative C-α RMSF plot shows the degree of flexibility of the studied compounds when bound to the MtrD protein for a period of 175 ns. (<b>D</b>) Comparative C-α RMSF plot, showing the degree of flexibility of the studied compounds when bound to the drug-binding site for a period of 175 ns. For both RMSD and RMSF plots, the black line graph represents data for the Apo protein (Unbound MtrD protein), the red line graph shows Apo-INH1, the green line graph shows Apo-INH2, the dark blue line graph shows Apo-INH3, the light blue line graph shows Apo-STD1, and the pink line graph shows Apo-STD2.</p>
Full article ">Figure 5
<p>Hoechest (bis-benzimide) accumulation assay in <span class="html-italic">Neisseria gonorrhoea</span> ATCC 49981 after treatment with <span class="html-italic">H. populifolium</span> compounds: 4,5-dicaffeoylquinic acid (orange line graph), apigenin-7-glucoside (gray line graph), and carvacrol (yellow line graph). PaβN was used as the positive control, while untreated <span class="html-italic">N. gonorrhoeae</span> was used as the negative control. The heat-inactivated <span class="html-italic">N. gonorrhoeae</span> ATCC 49981 cells serve as a point of reference for maximal dye accumulation due to the loss of membrane integrity, leading to a high influx and retention of the dye.</p>
Full article ">
19 pages, 4061 KiB  
Article
Discovery of a Small Molecule with an Inhibitory Role for RAB11
by Camille Lempicki, Julian Milosavljevic, Christian Laggner, Simone Tealdi, Charlotte Meyer, Gerd Walz, Konrad Lang, Carlo Cosimo Campa and Tobias Hermle
Int. J. Mol. Sci. 2024, 25(23), 13224; https://doi.org/10.3390/ijms252313224 - 9 Dec 2024
Viewed by 551
Abstract
RAB11, a pivotal RabGTPase, regulates essential cellular processes such as endocytic recycling, exocytosis, and autophagy. The protein was implicated in various human diseases, including cancer, neurodegenerative disorders, viral infections, and podocytopathies. However, a small-molecular inhibitor is lacking. The complexity and workload associated with [...] Read more.
RAB11, a pivotal RabGTPase, regulates essential cellular processes such as endocytic recycling, exocytosis, and autophagy. The protein was implicated in various human diseases, including cancer, neurodegenerative disorders, viral infections, and podocytopathies. However, a small-molecular inhibitor is lacking. The complexity and workload associated with potential assays make conducting large-scale screening for RAB11 challenging. We employed a tiered approach for drug discovery, utilizing deep learning-based computational screening to preselect compounds targeting a specific pocket of RAB11 protein with experimental validation by an in vitro platform reflecting RAB11 activity through the exocytosis of GFP. Further validation included the exposure of Drosophila by drug feeding. In silico pre-screening identified 94 candidates, of which 9 were confirmed using our in vitro platform for Rab11 activity. Focusing on compounds with high potency, we assessed autophagy, which independently requires RAB11, and validated three of these compounds. We further analyzed the dose–response relationship, observing a biphasic, potentially hormetic effect. Two candidate compounds specifically caused a shift in Rab11 vesicles to the cell periphery, without significant impact on Rab5 or Rab7. Drosophila larvae exposed to another candidate compound with predicted oral bioavailability exhibited minimal toxicity, subcellular dispersal of endogenous Rab11, and a decrease in RAB11-dependent nephrocyte function, further supporting an inhibitory role. Taken together, the combination of computational screening and experimental validation allowed the identification of small molecules that modify the function of Rab11. This discovery may further open avenues for treating RAB11-associated disorders. Full article
(This article belongs to the Special Issue Techniques and Strategies in Drug Design and Discovery, 2nd Edition)
Show Figures

Figure 1

Figure 1
<p>A screening platform for RAB11 and computational drug screening. (<b>a</b>) Schematic shows cycling of RAB proteins between the active state (GTP-bound) that is terminated by support of GAPs by hydrolysis of GTP to GDP, which in turn is displaced by GEFs to allow reactivation by GTP binding. (<b>b</b>) Schematic illustrates the screening platform. HEK293T cells express a secretory GFP that carries an <span class="html-italic">IFNA2</span>-derived signal peptide. Secretion is promoted by RAB11, so that reduction in GFP secretion into the supernatant indicates reduced activity of RAB11. (<b>c</b>,<b>c’</b>) Fluorescence microscopy image of HEK293T cells stably transduced with the secretory GFP shows that all cells are GFP-positive by comparing the nuclear stain (blue) with the green channel. (<b>d</b>) Immunoblotting with anti-GFP using cellular supernatants from different wells with HEK293T cells stably transduced with secretory GFP reveals strong, random variation in GFP positivity between different wells. (<b>e</b>) Transient transfection of HEK293T cells from (<b>c</b>,<b>d</b>) with RAB11-GEF SH3BP5 or empty vector shows strong increase in GFP from the cellular supernatant with activation of RAB11 after immunoblotting. (<b>f</b>) This panel illustrates the target domain on RAB11 used for computational screening. On the left, the structure of RAB11A is shown as a dimer (green) in complex with the effector FIP3 (PBD ID: 2HV8). The enlargement illustrates the binding pocket near GTP (yellow) and two switch regions. The targeted residues are blue. The right side of the panel shows the structure of RAB11B (green, PBD ID: 2F9M) with the binding pocket highlighted in red and overlay of RAB11A/FIP3 complex in yellow (PDB ID 2HV8, active form binding GTP) and the RAB11B/PKG II in magenta (PDB ID 4OJK, inactive form binding GDP) to illustrate the flexibility of the switch region and its interaction with effector proteins. The enlargement illustrates the binding pocket with the targeted residues. (<b>g</b>) The schematic illustrates the deep learning-based computational high-throughput screening using the AtomNet<sup>®</sup> technology (Atomwise Inc., San Francisco, CA, USA). Millions of commercially available compounds are screened virtually against the target structure before the selection of 94 compounds that are purchased for further testing.</p>
Full article ">Figure 2
<p>Screening identifies nine hits as inhibiting compounds. (<b>a</b>) Schematic illustrates the work flow of in vitro screening of compounds. (<b>b</b>) Representative Western blot shows GFP bands in the supernatant as an example. GFP is undetectable in control conditions (empty vector) but strongly enhanced after activation of RAB11 by transfection of GFP-<span class="html-italic">SH3BP5</span> with DMSO (vehicle), while compounds reduce secretion of GFP to a variable extent. (<b>c</b>) Quantification of immunoblot for all tested compounds analogous to (<b>b</b>) showing repeat measurements of compounds after censoring four compounds with excessively overshooting GFP secretion. Statistical significance was defined as <span class="html-italic">p</span> &lt; 0.01; individual <span class="html-italic">p</span>-values, see <a href="#app1-ijms-25-13224" class="html-app">Supplementary Table S2</a>. Bars marked in green represent the blinded negative controls. Grey background indicates control, blue background significant increase, red background significant decrease in GFP secretion. Censored: F6, A10, G6, and B10. Significantly activating, from left to right: B2, H9, C5, E6, and F1. Not significant, from left to right: F9, E1, E10, D12, C7, E7, B12, H2, B5, E9, A4, D2, C4, B4, D4, G11, A11, E12, A3, H6, H12 (blinded control 1), D7, B9, F10, A8, A12, G8, G10, A7, E11, F5, F3, G5, E4, B1, D10, D8, F8, G12 (blinded control 2), A2, B8, D11, H10, F11, F4, C9, H8, G4, D9, H7, D3, E2, H5, C11, B3, G3, A6, A9, E8, A5, D1, C12, F7, C8, H4, G7, H11, F12, B7, E3, F2, C3, G2, H1, G1, B11, and C10. Significantly inhibiting, from left to right: D6, G9, E5, B6, C6, H3, C2, D5, and A1. (<b>d</b>) Quantification of immunoblots analogous to (<b>b</b>) of nine compounds with an initially overshooting response show normal or even reduced activity after replicate measurement that did not differ significantly from the control (DMSO, mean ± SD, <span class="html-italic">n</span> = 3–5 per condition, <span class="html-italic">p</span> &gt; 0.05 for all compounds). This suggests unspecific toxicity as the cause of the previously observed excessive response. (<b>e</b>) Quantification of immunoblots analogous to (<b>b</b>) shows selection of nine hits with significant reduction in GFP secretion after censoring overshooting responses (mean ± SD). Statistical significance was defined as <span class="html-italic">p</span> &lt; 0.01; individual <span class="html-italic">p</span>-values, see <a href="#app1-ijms-25-13224" class="html-app">Supplementary Table S2</a>.</p>
Full article ">Figure 3
<p>Validation for potency, by detection of basal autophagy and subcellular localization. (<b>a</b>) Representative Western blot stained for secreted GFP in the supernatant at a dose of 5 µM shows variable effects using the lower dose, which is compatible with variable potency. (<b>b</b>) Quantification of immunoblotting using anti-GFP antibody on supernatant from HEK293T cells stably expressing secretory GFP after compound exposure at 5 µM is shown for seven compounds. Two of the nine compounds significant at 20 µM were censored here due to an excessive response. At the lower dose, only compounds B6, C6, D5, and D6 showed a significant reduction, while A1 showed a trend that was not significant (mean ± SD, <span class="html-italic">n</span> = 4–7 per condition, <span class="html-italic">p</span> &lt; 0.05 for D5, <span class="html-italic">p</span> &lt; 0.01 for D6 and C6, <span class="html-italic">p</span> &lt; 0.001 for B6. For the remaining compounds, <span class="html-italic">p</span> &gt; 0.05). (<b>c</b>) Schematic illustrates phagophore formation with activation of LC3-I to LC3II, which marks the autophagosomes. The phagophore elongates to form the mature autophagosome, which in turn fuses with the lysosome. RAB11 promotes both phagophore formation and the lysosomal fusion event. (<b>d</b>,<b>e</b>) Immunoblotting of lysates from HEK293T cells after compound exposure using anti-LC3B reveals a lower band around 15 kDa that reflects the active LC3B that travels faster due to lipidation. Cells have been treated with 80 µM chloroquine for 2 h to show basal autophagic flux. Treatment with compounds B6 and D5 (<b>d</b>) and D6 (<b>e</b>) reduces the lower band that corresponds to LC3-II. (<b>f</b>) Quantification of density of LC3-II/loading control analogous to experiment in (<b>c</b>) is shown for the indicated genotypes. Compounds D5, B6, and D6 show a significant reduction in basal autophagy, suggesting an effect on the activity of RAB11 (mean ± SD, <span class="html-italic">n</span> = 3–10 per condition, <span class="html-italic">p</span> &gt; 0.05 for A1 and C6, <span class="html-italic">p</span> &lt; 0.001 for D6, and <span class="html-italic">p</span> &lt; 0.0001 for B6 and D5). (<b>g</b>) Quantitative analysis of FRET efficiency (FRET ratio) is shown as readout of RAB11A-GTP loading after application of Rab11-inhibitor-D6 at 20 µM for 16 h compared to vehicle does not prevent GTP loading (mean ± SE, <span class="html-italic">n</span> = 53 cells for vehicle and 33 cells for Rab11-inhibitor-D6 condition, <span class="html-italic">p</span> &gt; 0.05). (<b>h</b>) Quantification of the number of Rab5 (left panel), Rab7 (middle panel), and Rab11 (right panel) vesicles per single Cos-7 cell in the peripheral region when treated with either DMSO (vehicle) or D6 or D5 or B6 compounds. Error bars represent mean ± S.E.M. n.s., not significant, <span class="html-italic">p</span> &lt; 0.05 (one-sample Student’s <span class="html-italic">t</span>-test), <span class="html-italic">n</span> = 3 independent experiments.</p>
Full article ">Figure 4
<p>Dose–response relationship indicates a hormetic response. (<b>a</b>) Shown is the structure and Simplified Molecular Input Line Entry System (SMILES) string of RAB11-inhibitor D5. (<b>b</b>) The dose–response curve illustrates a bell-shaped relationship between increasing doses of an RAB11-inhibitor-D5 treatment and the corresponding changes in GFP secretion. GFP was evaluated by densitometry after immunoblotting with anti-GFP using our secretory GFP HEK293T cells. The y-axis shows the normalized response of treated cells against the vehicle (DMSO) in percent that is plotted against the dose range in logarithmic scale on the x-axis. The data were fitted using non-linear regression for a biphasic, bell-shaped effect (blue line), with an R-squared value of 0.43. The logEC<sub>50</sub> values were 3.34 µM and 0.27 µM for Rab11-inhibitor-D5 (<span class="html-italic">n</span> = 2–5 per concentration). (<b>c</b>) Shown is the structure and Simplified Molecular Input Line Entry System (SMILES) string of RAB11-inhibitor B6. (<b>d</b>) The dose–response curve illustrates the biphasic relationship between increasing doses of an RAB11-inhibitor-B6 treatment and the corresponding changes in GFP analogous to (<b>b</b>). The data were fitted using non-linear regression for a biphasic, bell-shaped effect (blue line), with an R-squared value of 0.45. The logEC<sub>50</sub> values were determined as 3.34 µM and 0.10 µM for Rab11-inhibitor-B6 (<span class="html-italic">n</span> = 2–5 per concentration). (<b>e</b>) Shown is the structure and Simplified Molecular Input Line Entry System (SMILES) string of RAB11-inhibitor D6. (<b>f</b>) The dose–response curve shows a largely biphasic relationship between increasing doses of an RAB11-inhibitor-D6 treatment and the respective changes in GFP analogous to (<b>b</b>). The data were fitted using non-linear regression for a biphasic effect (blue line), with an R-squared value of 0.30. The resultant logEC<sub>50</sub> values were 2.73 and 1.83 µM for Rab11-inhibitor-D6 (<span class="html-italic">n</span> = 2–5 per concentration). (<b>g</b>) Quantification of immunoblotting using anti-GFP antibody on supernatant from HEK293T cells stably expressing secretory GFP after compound exposure at 1.25 µM is shown. There is a trend towards increased secretion that is statistically not significant for RAB11-inhibitor-B6 and RAB11-inhibitor-D5 and a statistically significant increase for RAB11-inhibitor-D6 (mean ± SD, <span class="html-italic">n</span> = 6–8 per genotype, <span class="html-italic">p</span> &gt; 0.05 for RAB11-inhibitor-B6 and RAB11-inhibitor-D5, <span class="html-italic">p</span> &lt; 0.001 for RAB11-inhibitor-D6).</p>
Full article ">Figure 5
<p>RAB11-inhibitors show no significant toxicity in vitro. (<b>a</b>–<b>e</b>) Immortalized podocytes were exposed to the respective compounds each at a concentration of 20 µM for 24 h preceding Annexin V/propidium iodide exposure and flow cytometry. Representative original dot plots (left) are shown for the indicated conditions. Green fluorescence indicates FITC-Annexin (apoptotic cells bottom right section in green) while red fluorescence represents propidium iodide (dead cells, upper left section in red). Cells negative for either cell death marker (bottom left section in red) or double positive cells (upper right section in blue) are shown as well. Corresponding histograms for green fluorescence under these conditions are displayed on the right. Elevated Annexin positivity compared to control (<b>b</b>) is observed for Doxorubicin (Adriamycin, panel a), but not for the novel inhibitors of RAB11 (<b>c</b>–<b>e</b>). (<b>f</b>) Quantification of data analogous to a-e (mean ± SD, <span class="html-italic">n</span> = 4, <span class="html-italic">p</span> &lt; 0.0001 for Adriamycin compared to control, <span class="html-italic">p</span> &gt; 0.05 for all RAB11-inhibitors).</p>
Full article ">Figure 6
<p>Drug exposure in <span class="html-italic">Drosophila</span> larvae confirms low toxicity and Rab11 inhibition by morphological and functional criteria. (<b>a</b>) Representative image showing <span class="html-italic">Drosophila</span> third instar larvae from a <span class="html-italic">Drosophila</span> strain similar to wild-type (yw<sup>1118</sup>) that are being exposed to RAB11-inhibitors or vehicle (DMSO) using 96-well plates and liquid food. (<b>b</b>) Quantification of surviving larvae after 24 h of drug exposure analogous to (<b>a</b>) as indicated by movement and feeding upon inspection, (<span class="html-italic">n</span> = 100 larvae per genotype). (<b>c</b>,<b>d</b>) Confocal images of garland cell nephrocytes stained for the slit diaphragm protein Pyd are shown after RAB11-inhibitor-D6 feeding (<b>d</b>) or DMSO control (<b>c</b>). (<b>e</b>–<b>h</b>) Representative confocal images of nephrocytes stained for RAB11 show increasing dispersal of Rab11 upon drug feeding and reflect four categories used for quantification (1: strong vesicular signal, low background, 2: strong vesicular signal, high background, 3: weak vesicular signal high background, 4: high background only). (<b>i</b>) Blinded quantification of data analogous to e-f using Chi-squared test (comparing two groups, categories 1 + 2 vs. 3 + 4) indicates a strong shift towards dispersal of RAB11 upon exposure to RAB11-inhibitor-D6 (<span class="html-italic">n</span> = 20 animals per genotype, <span class="html-italic">p</span> &lt; 0.05). (<b>j</b>) FITC-albumin endocytosis as an assay of nephrocyte function is shown after exposure for 30 s and wash out of 5 min. Exposing larvae to Rab11-inhibitor-D6 in liquid food for 24 h strongly reduces uptake of FITC-albumin compared with the control (DMSO). (<b>k</b>) Quantification of results as average of the three brightest individual cells per animal from (<b>j</b>) in ratio to a control experiment performed in parallel (mean ± SD, <span class="html-italic">n</span> = 10–12 animals per genotype, <span class="html-italic">p</span> &lt; 0.01 for exposure with Rab11-inhibitor-D6).</p>
Full article ">
17 pages, 4196 KiB  
Article
Integrative Machine Learning, Virtual Screening, and Molecular Modeling for BacA-Targeted Anti-Biofilm Drug Discovery Against Staphylococcal Infections
by Ahmad Almatroudi
Crystals 2024, 14(12), 1057; https://doi.org/10.3390/cryst14121057 - 6 Dec 2024
Viewed by 526
Abstract
The rise in antibiotic-resistant Staphylococcal infections necessitates innovative approaches to identify new therapeutic agents. This study investigates the application of machine learning models to identify potential phytochemical inhibitors against BacA, a target related to Staphylococcal infections. Active compounds were retrieved from BindingDB while [...] Read more.
The rise in antibiotic-resistant Staphylococcal infections necessitates innovative approaches to identify new therapeutic agents. This study investigates the application of machine learning models to identify potential phytochemical inhibitors against BacA, a target related to Staphylococcal infections. Active compounds were retrieved from BindingDB while the decoy was generated from DUDE. The RDKit was utilized for feature engineering. Machine learning models such as k-nearest neighbors (KNN), the support vector machine (SVM), random forest (RF), and naive Bayes (NB) were trained on an initial dataset consisting of 226 active chemicals and 2550 inert compounds. Accompanied by an MCC of 0.93 and an accuracy of 96%, the RF performed better. Utilizing the RF model, a library of 9000 phytochemicals was screened, identifying 300 potentially active compounds, of which 192 exhibited drug-like properties and were further analyzed through molecular docking studies. Molecular docking results identified Ergotamine, Withanolide E, and DOPPA as top inhibitors of the BacA protein, accompanied by interaction affinities of −8.8, −8.1, and −7.9 kcal/mol, respectively. Molecular dynamics (MD) was applied for 100 ns to these top hits to evaluate their stability and dynamic behavior. RMSD, RMSF, SASA, and Rg analyses showed that all complexes remained stable throughout the simulation period. Binding energy calculations using MMGBSA analysis revealed that the BacA_Withanolide E complex exhibited the most favorable binding energy profile with significant van der Waals interactions and a substantial reduction in gas-phase energy. It also revealed that van der Waals interactions contributed significantly to the binding stability of Withanolide E, while electrostatic interactions played a secondary role. The integration of machine learning models with molecular docking and MD simulations proved effective in identifying promising phytochemical inhibitors, with Withanolide E emerging as a potent candidate. These findings provide a pathway for developing new antibacterial agents against Staphylococcal infections, pending further experimental validation and optimization. Full article
Show Figures

Figure 1

Figure 1
<p>Scatter plot of PC1 vs. PC2 showing separation of active and inactive compounds.</p>
Full article ">Figure 2
<p>The chemical space and diversity distribution of the (<b>A</b>) training set and (<b>B</b>) test set are characterized by molecular weight and LogP.</p>
Full article ">Figure 3
<p>The ROC-AUC of all the models on the (<b>A</b>) test set and (<b>B</b>) train set.</p>
Full article ">Figure 4
<p>(<b>A</b>) Top five inhibitors for BacA protein. Three-dimensional interaction of (<b>B</b>) Ergotamine, (<b>C</b>) Withanolide E, (<b>D</b>) DOPPA, (<b>E</b>) Ergost-2-en-26-oic acid, and (<b>F</b>) Hydroxy-1-isomangostin. Two-dimensional interaction of (<b>G</b>) Ergotamine, (<b>H</b>) Withanolide E, (<b>I</b>) DOPPA, (<b>J</b>) Ergost-2-en-26-oic acid, and (<b>K</b>) Hydroxy-1-isomangostin.</p>
Full article ">Figure 5
<p>RMSD plot of the backbone atoms for the BacA–ligand complexes over a 100 ns molecular dynamics simulation. The graph represents the structural stability of the complex where lower RMSD values indicate a stable interaction.</p>
Full article ">Figure 6
<p>RMSF plots of the BacA protein-ligand complexes during the molecular dynamics simulation.</p>
Full article ">Figure 7
<p>SASA plot for the BacA protein-ligand complexes during the molecular dynamics simulation.</p>
Full article ">Figure 8
<p>Rg plots of the BacA protein-ligand complexes during the molecular dynamics simulation.</p>
Full article ">
19 pages, 7612 KiB  
Article
Identification of a Potential PGK1 Inhibitor with the Suppression of Breast Cancer Cells Using Virtual Screening and Molecular Docking
by Xianghui Chen, Zanwen Zuo, Xianbin Li, Qizhang Li and Lei Zhang
Pharmaceuticals 2024, 17(12), 1636; https://doi.org/10.3390/ph17121636 - 5 Dec 2024
Viewed by 477
Abstract
Background/Objectives: Breast cancer is the second most common malignancy worldwide and poses a significant threat to women’s health. However, the prognostic biomarkers and therapeutic targets of breast cancer are unclear. A prognostic model can help in identifying biomarkers and targets for breast cancer. [...] Read more.
Background/Objectives: Breast cancer is the second most common malignancy worldwide and poses a significant threat to women’s health. However, the prognostic biomarkers and therapeutic targets of breast cancer are unclear. A prognostic model can help in identifying biomarkers and targets for breast cancer. In this study, a novel prognostic model was developed to optimize treatment, improve clinical prognosis, and screen potential phosphoglycerate kinase 1 (PGK1) inhibitors for breast cancer treatment. Methods: Using data from the Gene Expression Omnibus (GEO) database, differentially expressed genes (DEGs) were identified in normal individuals and breast cancer patients. The biological functions of the DEGs were examined using bioinformatics analysis. A novel prognostic model was then constructed using the DEGs through LASSO and multivariate Cox regression analyses. The relationship between the prognostic model, survival, and immunity was also evaluated. In addition, virtual screening was conducted based on the risk genes to identify novel small molecule inhibitors of PGK1 from Chemdiv and Targetmol libraries. The effects of the potential inhibitors were confirmed through cell experiments. Results: A total of 230 up- and 325 down-regulated DEGs were identified in HER2, LumA, LumB, and TN breast cancer subtypes. A new prognostic model was constructed using ten risk genes. The analysis from The Cancer Genome Atlas (TCGA) indicated that the prognosis was poorer in the high-risk group compared to the low-risk group. The accuracy of the model was confirmed using the ROC curve. Furthermore, functional enrichment analyses indicated that the DEGs between low- and high-risk groups were linked to the immune response. The risk score was also correlated with tumor immune infiltrates. Moreover, four compounds with the highest score and the lowest affinity energy were identified. Notably, D231-0058 showed better inhibitory activity against breast cancer cells. Conclusions: Ten genes (ACSS2, C2CD2, CXCL9, KRT15, MRPL13, NR3C2, PGK1, PIGR, RBP4, and SORBS1) were identified as prognostic signatures for breast cancer. Additionally, results showed that D231-0058 (2-((((4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-yl)carbamoyl)methyl)sulfanyl)acetic acid) may be a novel candidate for treating breast cancer. Full article
(This article belongs to the Section Pharmacology)
Show Figures

Figure 1

Figure 1
<p>Identification and functional enrichment analysis of DEGs. (<b>A</b>–<b>D</b>) Top 20 up-regulated and down-regulated genes in HER2 (<b>A</b>), LumA (<b>B</b>), LumB (<b>C</b>), and TN (<b>D</b>) subtype tumor samples from GSE29431, GSE38959, GSE45827, GSE65194, and GSE115275 datasets. The red color represents up-regulated genes, while green indicates down-regulated genes. The numbers shown in the figure represent the log fold change (logFC) of genes in each dataset. The cutoff criteria are <span class="html-italic">p</span> &lt; 0.05 and |logFC| &gt; 0.5. (<b>E</b>) The Venn diagram of DEGs of HER2, LumA, LumB, and TN subtype tumor samples from GSE29431, GSE38959, GSE45827, GSE65194, and GSE115275 datasets. (<b>F</b>) The bar plot of GO functional enrichment analysis. The top 10 terms of biological process, cellular component, and molecular function are shown. (<b>G</b>) The bar plot illustrates the results of KEGG functional enrichment analysis.</p>
Full article ">Figure 2
<p>Analysis of the prognostic model in BC. (<b>A</b>) Forest plot of the signature risk model. (<b>B</b>) Lasso model for screening the key genes. (<b>C</b>) Multivariate Cox analysis confirming hub genes for risk model. (<b>D</b>) The expression levels of ten hub genes in breast cancer tissues compared to normal tissues. (<b>E</b>,<b>G</b>,<b>I</b>) Kaplan–Meier analysis of survival differences between high-risk and low-risk groups in training (<b>E</b>), test (<b>G</b>), and entire (<b>I</b>) sets. (<b>F</b>,<b>H</b>,<b>J</b>) Receiver operating characteristic (ROC) curve analysis on the ten model gene signatures in the training (<b>F</b>), test (<b>H</b>), and entire (<b>J</b>) sets. AUC, the area under the curve. These curves are performed by R package survival ROC. (<b>K</b>) Univariate Cox analysis of risk score and clinicopathological features in the entire set. (<b>L</b>) Multivariate Cox analysis of clinicopathological features and risk score in the entire set. (<b>M</b>) The ROC curve of the risk score and clinical characteristics. (<b>N</b>) The ROC curve and AUC values for the predictive signature at 1-year, 3-year, and 5-year survival rates.</p>
Full article ">Figure 3
<p>Analysis of the relationships between risk score and clinical characteristics of breast cancer in the TCGA cohort. (<b>A</b>) Heat map of ten model genes and clinical characteristics in the high- and low-risk groups. *, <span class="html-italic">p</span> &lt; 0.05; **, <span class="html-italic">p</span> &lt; 0.01; and ***, <span class="html-italic">p</span> &lt; 0.001. (<b>B</b>) Analysis of overall survival in TCGA-BC patients based on clinical stratification, focusing on high- and low-risk groups by age, clinical stage, N stage, and T stage.</p>
Full article ">Figure 4
<p>The nomogram in predicting overall survival of breast cancer. (<b>A</b>) The nomogram predicts 1-, 3-, and 5-year overall survival. (<b>B</b>) Calibration maps were utilized to predict survival rates at 1, 3, and 5 years.</p>
Full article ">Figure 5
<p>Analysis of functional enrichment across different risk groups. (<b>A</b>) Volcano chart of differentially expressed genes; (<b>B</b>) GO analysis explored the potential function in terms of biological process (BP), cellular component (CC), and molecular function (MF); (<b>C</b>) KEGG analysis showed the potential pathway enrichment; (<b>D</b>) GSEA analysis demonstrated the potential activated and suppressed pathway enrichment in the high-risk group compared with the low-risk group.</p>
Full article ">Figure 6
<p>Immune features analysis in risk groups. (<b>A</b>,<b>B</b>) ssGSEA (single-sample gene set enrichment analysis) scores for immune cells (<b>A</b>) and immune function (<b>B</b>) in TCGA cohort. (<b>C</b>) The expression of immune checkpoint-related genes and the correlation between risk scores. aDCs, activated dendritic cells; APC, antigen-presenting cell; CCR, chemokine receptor; HLA, human leukocyte antigen; iDCs, immature dendritic cells; IFN, interferon; MHC, major histocompatibility complex; NK, natural killer; pDCs, plasmacytoid dendritic cells; Tfh, T follicular helper; Th, T helper cell; TIL, tumor-infiltrating lymphocyte; Treg, T regulatory cell. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001; ns, non-significant.</p>
Full article ">Figure 7
<p>Three-dimensional interaction between PGK1 (2X13) and D715-2871 (<b>A</b>), Y040-8304 (<b>B</b>), D715-0344 (<b>C</b>), and D231-0058 (<b>D</b>). Yellow dotted lines represent hydrogen bonds, pinkish-red dotted lines represent salt bridges, and green balls depict magnesium ions.</p>
Full article ">Figure 8
<p>Inhibitory activity of D715-2871, Y040-8304, D715-0344, and D231-0058 against breast cancer cells T-47D and MCF-7. (<b>A</b>) CCK8 assay for cell viability. Cancer cells were treated with D715-2871, Y040-8304, D715-0344, or D231-0058 (0, 0.1, 1, 10, and 100 μg/mL) for 24 h. Data were presented as mean ± SD (<span class="html-italic">n</span> = 6). (<b>B</b>) CCK8 assay for cell viability. Cancer cells were treated with D231-0058 (0, 1, 3, 10, 30, and 100 μg/mL) for 24 and 48 h. Data were presented as mean ± SD (<span class="html-italic">n</span> = 6). (<b>C</b>) Microscopic observation of the cells treated with D231-0058 (0, 1, 3, 10, 30, and 100 μg/mL) for 24 h.</p>
Full article ">
19 pages, 484 KiB  
Article
Preventing Dysgraphia: Early Observation Protocols and a Technological Framework for Monitoring and Enhancing Graphomotor Skills
by Silvia Ceccacci, Arianna Taddei, Noemi Del Bianco, Catia Giaconi, Dolors Forteza Forteza and Francisca Moreno-Tallón
Information 2024, 15(12), 781; https://doi.org/10.3390/info15120781 - 5 Dec 2024
Viewed by 492
Abstract
Writing is first-order instrumental learning that develops throughout the life cycle, a complex process evolving from early childhood education. The identification of risk predictors of dysgraphia at age 5 has the potential to significantly reduce the impact of graphomotor difficulties in early primary [...] Read more.
Writing is first-order instrumental learning that develops throughout the life cycle, a complex process evolving from early childhood education. The identification of risk predictors of dysgraphia at age 5 has the potential to significantly reduce the impact of graphomotor difficulties in early primary school, which affects handwriting performance to such an extent that it can become illegible. Building on established scientific literature, this study focuses on screening processes, with particular attention to writing requirements. This paper proposes a novel prevention and intervention system based on new technologies for teachers and educators or therapists. Specifically, it presents a pilot study testing an innovative tactile device to analyze graphomotor performance and motor coordination in real time. The research explores whether this haptic device can be used as an effective pedagogical aid for preventing graphomotor issues in children aged 5 to 6 years. The results showed a high level of engagement and usability among young participants. Furthermore, the quality of graphomotor traces, respectively executed by children after virtual and physical training, were comparable, supporting the use of the tool as a complementary training resource for the observation and enhancement of graphomotor processes. Full article
Show Figures

Figure 1

Figure 1
<p>The proposed technological framework.</p>
Full article ">Figure 2
<p>Example of considered graphomotor paths (on the <b>left</b>). Example of wooden graphomotor boards (in the <b>middle</b>). An example of a virtual object used for haptic training (on the <b>right</b>).</p>
Full article ">Figure 3
<p>Exercise repetitions performed with haptic device and wooden board.</p>
Full article ">Figure 4
<p>Accuracy of the drawing of the three patterns achieved after haptic and wooden tablet training.</p>
Full article ">
11 pages, 2298 KiB  
Article
Results of a Codesign Process: A Cognition Screening Pathway for Inpatient and Outpatient Settings for Patients Who Are Facing or Have Undergone Lower Limb Amputation
by Erinn Dawes, Lyndel Hewitt, Vida Bliokas and Val Wilson
J. Clin. Med. 2024, 13(23), 7378; https://doi.org/10.3390/jcm13237378 - 4 Dec 2024
Viewed by 387
Abstract
Background/Objectives: Cognition plays a major role in prosthetic rehabilitation success. The ability to identify patients who may have difficulty understanding and adapting to the rehabilitation process is beneficial for clinicians and patients to allow for targeted and appropriate therapy. The research aim [...] Read more.
Background/Objectives: Cognition plays a major role in prosthetic rehabilitation success. The ability to identify patients who may have difficulty understanding and adapting to the rehabilitation process is beneficial for clinicians and patients to allow for targeted and appropriate therapy. The research aim was to codesign a process that facilitates routine cognitive screening into the amputee inpatient journey. Methods: A convenience sample of sixteen medical and allied health practitioners from one local health district undertook a codesign process over 10 months from March to November 2023. A combination of virtual and face-to-face data collection occurred. Each of the codesign meetings was audio recorded, following which transcription occurred. Transcripts were reviewed using thematic analysis-based techniques to capture themes and consensus within the group. Results: Two pathways were established for use within one local health district, allowing clinicians to measure the cognition of patients in both inpatient and outpatient settings either before or after they underwent amputation. The newly established pathways provide step-by-step guidance for clinicians, such as how to address contraindicators for testing and providing guidance for subsequent neuropsychological testing. The Montreal Cognitive Assessment (MoCA), both paper based and electronic based, was selected as the cognitive screening tool for implementation. Conclusions: Utilizing codesign as a method for generating a cognitive screening pathway for amputees was successful. The pathways generated should be reviewed for suitability for application in other health settings. Full article
(This article belongs to the Section Clinical Rehabilitation)
Show Figures

Figure 1

Figure 1
<p>Criteria for neuropsychological examination following cognitive screen.</p>
Full article ">Figure 2
<p>Screening Pathway for Amputee Cognition (SPArC)—inpatient pathway.</p>
Full article ">Figure 3
<p>Screening Pathway for Amputee Cognition (SPArC)—outpatient pathway.</p>
Full article ">
22 pages, 5139 KiB  
Article
Evaluating the Binding Potential and Stability of Drug-like Compounds with the Monkeypox Virus VP39 Protein Using Molecular Dynamics Simulations and Free Energy Analysis
by Ahmed M. Hassan, Hattan S. Gattan, Arwa A. Faizo, Mohammed H. Alruhaili, Azzah S. Alharbi, Leena H. Bajrai, Ibrahim A. AL-Zahrani, Vivek Dhar Dwivedi and Esam I. Azhar
Pharmaceuticals 2024, 17(12), 1617; https://doi.org/10.3390/ph17121617 - 30 Nov 2024
Viewed by 676
Abstract
Background/Objectives: Monkeypox is a re-emerging viral disease with features of infectiously transmitted zoonoses. It is now considered a public health priority because of its rising incidence and transmission from person to person. Monkeypox virus (MPXV) VP39 protein is identified as an essential protein [...] Read more.
Background/Objectives: Monkeypox is a re-emerging viral disease with features of infectiously transmitted zoonoses. It is now considered a public health priority because of its rising incidence and transmission from person to person. Monkeypox virus (MPXV) VP39 protein is identified as an essential protein for replication of the virus, and therefore, it is a potential target for antiviral drugs. Methods: This work analyzes the binding affinities and the differential conformational stability of three target compounds and one control compound with the VP39 protein through multiple computational methods. Results: The re-docking analysis revealed that the compounds had high binding affinities towards the target protein; among these compounds, compounds 1 and 2 showed the highest binding energies in the virtual screening, and thus, these were considered as the most active inhibitor candidates. Intermolecular interaction analysis revealed distinct binding mechanisms. While compound 1 had very strong hydrogen bonds and hydrophobic interactions, compound 2 had numerous water-mediated interactions, and compound 3 had only ionic and hydrophobic contacts. In molecular dynamic simulations, compounds 1 and 2 showed that the protein–ligand complexes had a stable conformation, with protein RMSD values around 2 Å for both compounds. In contrast, compound 3 was slightly flexible, and the control compound was more flexible. MM/GBSA analysis again supported these results, which gave the binding free energies that were also supportive for these compounds. Conclusions: Notably, all the selected compounds, especially compounds 1 and 2, demonstrate high binding affinity. Therefore, these compounds can be further tested as antiviral agents against monkeypox treatment. Full article
Show Figures

Figure 1

Figure 1
<p>Three-dimensional and two-dimensional structure analysis of four selected compounds in the docked pocket of selected compounds, i.e., (<b>a</b>,<b>b</b>) compound <b>1</b>, (<b>c</b>,<b>d</b>) compound <b>2</b>, (<b>e</b>,<b>f</b>) compound <b>3</b>, and (<b>g</b>,<b>h</b>) the control. The red color in ligand represents oxygen, while the blue color represents nitrogen, and the yellow color represents Sulfur.</p>
Full article ">Figure 2
<p>Protein RMSD triplicate in complex with three compounds and one control. (<b>a</b>) Compound <b>1</b>, (<b>b</b>) Compound <b>2</b>, (<b>c</b>) Compound <b>3</b>, and (<b>d</b>) Control.</p>
Full article ">Figure 3
<p>Ligand RMSD triplicate in complex with three compounds and one control. (<b>a</b>) Compound <b>1</b>, (<b>b</b>) Compound <b>2</b>, (<b>c</b>) Compound <b>3</b>, and (<b>d</b>) Control.</p>
Full article ">Figure 4
<p>Protein RMSF of top selected compound in complex with control complex. (<b>a</b>) Compound <b>1</b>, (<b>b</b>) Compound <b>2</b>, (<b>c</b>) Compound <b>3</b>, and (<b>d</b>) Control.</p>
Full article ">Figure 5
<p>Ligand RMSF triplicate in complex with three compounds and one control. (<b>a</b>) Compound <b>1</b>, (<b>b</b>) Compound <b>2</b>, (<b>c</b>) Compound <b>3</b>, and (<b>d</b>) Control.</p>
Full article ">Figure 6
<p>Protein–ligand profiling of selected compounds in the docked pocket of selected protein, i.e., (<b>a</b>) compound <b>1</b>, (<b>b</b>) compound <b>2</b>, (<b>c</b>) compound <b>3</b> and, (<b>d</b>) the control.</p>
Full article ">Figure 7
<p>Two-dimensional protein–ligand interaction analysis of selected compounds in the docked pocket of target protein, i.e., (<b>a</b>) compound <b>1</b>, (<b>b</b>) compound <b>2</b>, (<b>c</b>) compound <b>3</b> and, (<b>d</b>) the control.</p>
Full article ">Figure 8
<p>SASA analysis of selected compounds in the docked pocket of target protein, i.e., (<b>a</b>) compound <b>1</b>, (<b>b</b>) compound <b>2</b>, (<b>c</b>) compound <b>3</b> and, (<b>d</b>) the control.</p>
Full article ">Figure 9
<p>RG analysis of selected compounds in the docked pocket of the target protein, i.e., (<b>a</b>) compound <b>1</b>, (<b>b</b>) compound <b>2</b>, (<b>c</b>) compound <b>3</b> and, (<b>d</b>) the control.</p>
Full article ">
13 pages, 578 KiB  
Article
Mental Health Symptom Reporting to a Virtual Triage Engine Prior to and During the COVID-19 Pandemic
by George A. Gellert, Aleksandra Kabat-Karabon, Tim Price, Gabriel L. Gellert, Kacper Kuszczyński, Mateusz Nowak and Piotr M. Orzechowski
COVID 2024, 4(12), 1908-1920; https://doi.org/10.3390/covid4120134 - 29 Nov 2024
Viewed by 426
Abstract
Objective: To examine patient-user symptom reporting to an AI-based online virtual triage (VT) and care-referral engine to assess patterns of mental health symptoms (MHS) reporting prior to and during the COVID-19 pandemic. Methods: The frequencies of 11 MHS reported through VT were analyzed [...] Read more.
Objective: To examine patient-user symptom reporting to an AI-based online virtual triage (VT) and care-referral engine to assess patterns of mental health symptoms (MHS) reporting prior to and during the COVID-19 pandemic. Methods: The frequencies of 11 MHS reported through VT were analyzed over three time intervals: one year prior to the WHO declaring a global COVID-19 emergency; from pandemic declaration to a mid-point in US vaccine distribution/uptake; and one year thereafter. Results: A total of 4,346,987 VT encounters/interviews presenting somatic and MHS occurred, increasing over time and peaking in the COVID-19 post-vaccine interval with 2,257,553 encounters (51.9%). In 866,218 encounters (19.9%), at least one MHS was reported. MHS reporting declined across subsequent time intervals, was lowest in the COVID-19 post-vaccine period (19.1%), and slightly higher in the pre-pandemic and COVID-19 pre-vaccine intervals (p = 0.05). The most frequently reported symptoms were anxiety, sleep disorder, general anxiety, irritability, and nervousness. Women reported anxiety less often and nervousness and irritability more often. Individuals aged 60+ years reported anxiety and nervousness less frequently, insomnia and sleep disorder more often than individuals 18–39 and 40–59 years old, and sleep disorder more often than those aged 40–59 years in all periods (all p = 0.05). Conclusions: Overall VT usage for somatic and mental health symptom reporting and care referral increased dramatically during the pandemic. VT effectively screened and provided care referral for patient-users presenting with MHS. Virtual triage offers a valuable additional vehicle to detect mental health symptoms and potentially accelerate care referral for patients needing care. Full article
Show Figures

Figure 1

Figure 1
<p>Percentage of Patient-Users Reporting Any Mental Health Symptom by COVID-19 Pandemic Time Interval. Notes: Time periods are interval I—COVID-19 pre-pandemic outbreak period (1 February 2019 to 29 January 2020); interval II—COVID-19 pre-vaccine pandemic period (30 January 2020 to 13 December 2020); and interval III—COVID-19 post-vaccine pandemic period (14 December 2020 to 13 December 2021). Differences between pandemic time intervals are statistically significant at <span class="html-italic">p</span> = 0.05.</p>
Full article ">Figure 2
<p>Mental health Symptoms Reported Among All Symptoms by COVID-19 Pandemic Time Period. Notes: Time periods are interval I—COVID-19 pre-pandemic outbreak period (1 February 2019 to 29 January 2020); interval II—COVID-19 pre-vaccine pandemic period (30 January 2020 to 13 December 2020); and interval III—COVID-19 post-vaccine pandemic period (14 December 2020 to 13 December 2021).</p>
Full article ">
18 pages, 4049 KiB  
Article
Natural Compounds Targeting Thymic Stromal Lymphopoietin (TSLP): A Promising Therapeutic Strategy for Atopic Dermatitis
by Muhammad Suleman, Chiara Moltrasio, Paola Maura Tricarico, Angelo Valerio Marzano and Sergio Crovella
Biomolecules 2024, 14(12), 1521; https://doi.org/10.3390/biom14121521 - 27 Nov 2024
Viewed by 473
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease with rising prevalence, marked by eczematous lesions, itching, and a weakened skin barrier often tied to filaggrin gene mutations. This breakdown allows allergen and microbe entry, with thymic stromal lymphopoietin (TSLP) playing a crucial [...] Read more.
Atopic dermatitis (AD) is a chronic inflammatory skin disease with rising prevalence, marked by eczematous lesions, itching, and a weakened skin barrier often tied to filaggrin gene mutations. This breakdown allows allergen and microbe entry, with thymic stromal lymphopoietin (TSLP) playing a crucial role by activating immune pathways that amplify the allergic response. TSLP’s central role in AD pathogenesis makes it a promising therapeutic target. Consequently, in this study, we used the virtual drug screening, molecular dynamics simulation, and binding free energies calculation approaches to explore the African Natural Product Database against the TSLP protein. The molecular screening identified four compounds with high docking scores, namely SA_0090 (−7.37), EA_0131 (−7.10), NA_0018 (−7.03), and WA_0006 (−6.99 kcal/mol). Furthermore, the KD analysis showed a strong binding affinity of these compounds with TSLP, with values of −5.36, −5.36, −5.34, and −5.32 kcal/mol, respectively. Moreover, the strong binding affinity of these compounds was further validated by molecular dynamic simulation analysis, which revealed that the WA_0006-TSLP is the most stable complex with the lowest average RMSD. However, the total binding free energies were −40.5602, −41.0967, −27.3293, and −51.3496 kcal/mol, respectively, showing the strong interaction between the selected compounds and TSLP. Likewise, these compounds showed excellent pharmacokinetics characteristics. In conclusion, this integrative approach provides a foundation for the development of safe and effective treatments for AD, potentially offering relief to millions of patients worldwide. Full article
(This article belongs to the Special Issue Novel Insights into Autoimmune/Autoinflammatory Skin Diseases)
Show Figures

Figure 1

Figure 1
<p>Bonding network analysis of SA_0090–TSLP and EA_0131-TSLP complexes. (<b>a</b>) shows the stick representation of the bonding network of the SA_0090-TSLP complex. (<b>b</b>) shows the stick representation of the bonding network of the EA_0131-TSLP complex.</p>
Full article ">Figure 2
<p>Bonding network analysis of NA_0018-TSLP and WA_0006-TSLP complexes. (<b>a</b>) shows the stick representation of the bonding network of the NA_0018-TSLP complex. (<b>b</b>) shows the stick representation of the bonding network of the WA_0006-TSLP complex.</p>
Full article ">Figure 3
<p>Dynamic stability analysis of shortlisted drug-TSLP complexes. (<b>a</b>) The trajectories of the RMSD for the EA_0131-TSLP complex over time. (<b>b</b>) The trajectories of the RMSD for the NA_0018-TSLP complex over time. (<b>c</b>) The trajectories of the RMSD for the SA_0090-TSLP complex over time. (<b>d</b>) The trajectories of the RMSD for the WA_0006-TSLP complex over time.</p>
Full article ">Figure 4
<p>Post-simulation trajectory analysis for residual compactness of shortlisted compound-TSLP complexes. (<b>a</b>) represents the compactness of the EA_0131-TSLP complex. (<b>b</b>) represents the compactness of the NA_0018-TSLP complex. (<b>c</b>) represents the compactness of the SA_0090-TSLP complex. (<b>d</b>) represents the compactness of the WA_0006-TSLP complex.</p>
Full article ">Figure 5
<p>(<b>a</b>) Post-simulation trajectory analysis for the RMSF of shortlisted compound-TSLP complexes. Note: the different colors show the specific compounds. (<b>b</b>) Showing the fluctuating regions of EA_0131-TSLP complex. (<b>c</b>) Showing the fluctuating regions of NA_0018-TSLP complex. (<b>d</b>) Showing the fluctuating regions of SA_0090-TSLP complex. (<b>e</b>) Showing the fluctuating regions of WA_0006-TSLP complex.</p>
Full article ">Figure 6
<p>Post-simulation hydrogen bond analysis of shortlisted compound-TSLP complexes. (<b>a</b>) represents the post-simulation trajectories of average hydrogen bonds in the EA_0131-TSLP complex. (<b>b</b>) represents the post-simulation trajectories of average hydrogen bonds in the NA_0018-TSLP complex. (<b>c</b>) represents the post-simulation trajectories of average hydrogen bonds in the SA_0090-TSLP complex. (<b>d</b>) represents the post-simulation trajectories of average hydrogen bonds in the WA_0006-TSLP complex.</p>
Full article ">
7 pages, 1719 KiB  
Proceeding Paper
Exploring Schiff Bases as Promising Alternatives to Traditional Drugs in the In Silico Treatment of Anti-Leishmaniasis as Trypanothione Reductase Inhibitors
by Diego R. Peixoto, Carlos S. H. Shiraishi, Rui M. V. Abreu, Osmair V. Oliveira and José D. dos Santos
Proceedings 2024, 102(1), 55; https://doi.org/10.3390/proceedings2024102055 - 25 Nov 2024
Viewed by 443
Abstract
Leishmaniasis, caused by the protozoan Leishmania spp. and transmitted by sandflies, affects 2 million people worldwide yearly and is recognized as a global problem by the WHO. Current treatments, including amphotericin B, Pentamidine, and Glucantime, show limited efficacy and serious side effects. Trypanothione [...] Read more.
Leishmaniasis, caused by the protozoan Leishmania spp. and transmitted by sandflies, affects 2 million people worldwide yearly and is recognized as a global problem by the WHO. Current treatments, including amphotericin B, Pentamidine, and Glucantime, show limited efficacy and serious side effects. Trypanothione reductase is a promising protein target for developing new promising drugs against Leishmaniasis. This study explores Schiff base compounds as potential alternatives to current treatments by inhibiting trypanothione reductase. Thirty-nine structures from the PubChem database were selected and analyzed using AutoDock Vina 1.1, an in silico molecular docking tool. Promising Schiff base candidates, indicated as compound 21 (3-Quinolinamine, N-(2-quinolinylmethylene)-, compound 24 (1,3-Bis[(E)-(2-Amino-4-Ethyl-5-Hydroxy-Phenyl)Methyleneamino]Urea, and compound 39 (Naphtaldehyde disulfide Schiff base), exhibited significant inhibitory binding affinity against trypanothione reductase, outperforming commercial inhibitors. Therefore, the present study proposes alternative Schiff base compounds for treating Leishmaniasis. Full article
Show Figures

Figure 1

Figure 1
<p>General equation for the formation of the Schiff base compounds.</p>
Full article ">Figure 2
<p>Compounds that make up the Schiff base library (<b>1</b>–<b>39</b>) and commercial inhibitors with their respective CID (PubChem Compound Identification, an access identifier with integers for identifying chemical structures in the database) codes.</p>
Full article ">Figure 3
<p>In (<b>A</b>), trypanothione reductase (PDB: 2JK6) is depicted in cartoon format overlaid with the surface and the Schiff base inhibitors. These inhibitors are shown in stick format and are colored according to the following legend: (<b>B</b>) Compound <b>21</b> (3-Quinolinamine, N-(2-quinolinylmethylene)-), (<b>C</b>) Compound <b>24</b> (2-((3-(1,3-Benzodioxol-5-yl)-2-methylpropylidene)amino)benzoic amethyl ester), and (<b>D</b>) Compound <b>39</b> (Benzoic acid, 2-((2-(phenylmethylene)octylidene)amino)-, methyl ester).</p>
Full article ">Figure 4
<p>In trypanothione reductase (PDB: 2JK6) is represented using the cartoon format overlaid with the surface. This representation allows the identification of the commercial inhibitors in the enzyme’s active site. These inhibitors are shown in stick format and are colored according to the following legend: (<b>A</b>) Amphotericin B (Green), (<b>B</b>) Glucantime (Pool Blue), (<b>C</b>) Miltefosine (Pink), (<b>D</b>) Paromomycin (Yellow), and (<b>E</b>) Pentamidine (Orange).</p>
Full article ">
Back to TopTop